Proqr Therapeutics Bv Stock Today
| PRQR Stock | USD 2.01 0.01 0.50% |
Performance0 of 100
| Odds Of DistressLess than 40
|
ProQR Therapeutics is selling at 2.01 as of the 25th of April 2024; that is -0.5 percent down since the beginning of the trading day. The stock's lowest day price was 2.01. ProQR Therapeutics has about a 40 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for ProQR Therapeutics BV are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of September 2014 | Category Healthcare | Classification Health Care |
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. The company has 81.35 M outstanding shares of which 261.07 K shares are at this time shorted by private and institutional investors with about 1.31 trading days to cover. More on ProQR Therapeutics BV
Follow Valuation Options Odds of Bankruptcy
Financial Report 21st of May 2024
ProQR Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. ProQR Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ProQR Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Daniel Boer | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering ProQR Therapeutics report their recommendations after researching ProQR Therapeutics' financial statements, talking to executives and customers, or listening in on ProQR Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering ProQR Therapeutics. The ProQR consensus assessment is calculated by taking the average forecast from all of the analysts covering ProQR Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to ProQR Therapeutics' liquidity, profitability, solvency, and operating efficiency, ProQR Therapeutics BV is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of ProQR Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
ProQR Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to ProQR Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ProQR Therapeutics' financial leverage. It provides some insight into what part of ProQR Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
ProQR Therapeutics BV (PRQR) is traded on NASDAQ Exchange in USA. It is located in Zernikedreef 9, Leiden, Netherlands, 2333 CK and employs 156 people. ProQR Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 164.34 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ProQR Therapeutics's market, we take the total number of its shares issued and multiply it by ProQR Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. ProQR Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 81.35 M outstanding shares of which 261.07 K shares are at this time shorted by private and institutional investors with about 1.31 trading days to cover.
ProQR Therapeutics BV currently holds about 156.4 M in cash with 21.11 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ProQR Therapeutics Probability Of Bankruptcy
Ownership AllocationProQR Therapeutics owns a total of 81.35 Million outstanding shares. 30% of ProQR Therapeutics BV outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check ProQR Ownership Details
ProQR Stock Price Odds Analysis
In regard to a normal probability distribution, the odds of ProQR Therapeutics jumping above the current price in 90 days from now is about 75.99%. The ProQR Therapeutics BV probability density function shows the probability of ProQR Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.4769 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, ProQR Therapeutics will likely underperform. Additionally, proQR Therapeutics BV has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of ProQR Therapeutics to move above the current price in 90 days from now is about 75.99 (This ProQR Therapeutics BV probability density function shows the probability of ProQR Stock to fall within a particular range of prices over 90 days) .
ProQR Stock Institutional Holders
Institutional Holdings refers to the ownership stake in ProQR Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ProQR Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ProQR Therapeutics' value.| Instituion | Recorded On | Shares | |
| Franklin Street Advisors Inc. | 2023-12-31 | 150 K | |
| Squarepoint Ops Llc | 2023-12-31 | 128.2 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 113.7 K | |
| Two Sigma Investments Llc | 2023-12-31 | 99.5 K | |
| Boothbay Fund Management, Llc | 2023-12-31 | 95.7 K | |
| Bank Of America Corp | 2023-12-31 | 78.3 K | |
| Geode Capital Management, Llc | 2023-12-31 | 46.7 K | |
| Virtu Financial Llc | 2023-12-31 | 34.9 K | |
| Resources Investment Advisors Inc | 2023-12-31 | 31.9 K | |
| Privium Fund Management B.v. | 2023-12-31 | 5.3 M | |
| Adage Capital Partners Gp Llc | 2023-12-31 | 3.6 M |
ProQR Therapeutics Historical Income Statement
ProQR Therapeutics BV Income Statement is one of the three primary financial statements used for reporting ProQR's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of ProQR Therapeutics revenue and expense. ProQR Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, ProQR Therapeutics' Total Other Income Expense Net is relatively stable compared to the past year. As of 04/25/2024, Interest Income is likely to grow to about 2.7 M, while Selling General Administrative is likely to drop slightly above 12.6 M. View More FundamentalsProQR Stock Against Markets
Picking the right benchmark for ProQR Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in ProQR Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for ProQR Therapeutics is critical whether you are bullish or bearish towards ProQR Therapeutics BV at a given time. Please also check how ProQR Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in ProQR Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Commodity Channel Now
Commodity ChannelUse Commodity Channel Index to analyze current equity momentum |
| All Next | Launch Module |
ProQR Therapeutics Corporate Management
Elected by the shareholders, the ProQR Therapeutics' board of directors comprises two types of representatives: ProQR Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ProQR. The board's role is to monitor ProQR Therapeutics' management team and ensure that shareholders' interests are well served. ProQR Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ProQR Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Domenico Valerio | Founder Board | Profile | |
| Robert Cornelisse | Chief People and Organization | Profile | |
| Sarah Kiely | Vice Communications | Profile | |
| Rene Beukema | Chief Corporate Devel. Officer, General Counsel, Corporate Secretary and Member of Management Board | Profile | |
| David Rodman | Chief Development Strategy Officer | Profile |
How to buy ProQR Stock?
Before investing in ProQR Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in ProQR Therapeutics. To buy ProQR Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of ProQR Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase ProQR Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located ProQR Therapeutics BV stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased ProQR Therapeutics BV stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as ProQR Therapeutics BV, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy ProQR Stock please use our How to Invest in ProQR Therapeutics guide.
Already Invested in ProQR Therapeutics BV?
The danger of trading ProQR Therapeutics BV is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ProQR Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ProQR Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ProQR Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ProQR Therapeutics is a strong investment it is important to analyze ProQR Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ProQR Therapeutics' future performance. For an informed investment choice regarding ProQR Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProQR Therapeutics BV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for ProQR Stock analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is ProQR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProQR Therapeutics. If investors know ProQR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProQR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 0.081 | Quarterly Revenue Growth 1.712 | Return On Assets (0.14) | Return On Equity (0.51) |
The market value of ProQR Therapeutics is measured differently than its book value, which is the value of ProQR that is recorded on the company's balance sheet. Investors also form their own opinion of ProQR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ProQR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProQR Therapeutics' market value can be influenced by many factors that don't directly affect ProQR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProQR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProQR Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProQR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.